Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 5/20 | 0.60 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.60 |
| ▸ | CHRNA1 | P02708 | 2/20 | 0.60 |
| ▸ | CHRNG | P07510 | 2/20 | 0.60 |
| ▸ | CHRNB1 | P11230 | 2/20 | 0.60 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.60 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.60 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.60 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.60 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.60 |
| ▸ | CHRND | Q07001 | 2/20 | 0.60 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.60 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.60 |
| ▸ | HRH1 | P35367 | 1/20 | 0.60 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.60 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | BLM | P54132 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1093383 | 0.82 | SLC6A2 (0.56) | SLC6A2SLC6A3CHRNA1CHRNGCHRNB1 | |
| SCHEMBL20809637 | 0.82 | SLC6A2 (0.56) | SLC6A2SLC6A3CHRNA1CHRNGCHRNB1 | |
| SCHEMBL30471336 | 0.82 | CYP2B6 (0.58) | SLC6A2SLC6A3CHRNA1CHRNGCHRNB1 | |
| SCHEMBL29018403 | 0.82 | CYP2B6 (0.58) | SLC6A2SLC6A3CHRNA1CHRNGCHRNB1 | |
| SCHEMBL23571741 | 0.79 | SLC6A2 (0.65) | SLC6A2SLC6A3CHRNA1CHRNGCHRNB1 | |
| SCHEMBL9431079 | 0.78 | SLC6A2 (0.50) | SLC6A2SLC6A3CHRNA1CHRNGCHRNB1 | |
| SCHEMBL8159886 | 0.78 | SLC6A2 (0.63) | SLC6A2SLC6A3CHRNA1CHRNGCHRNB1 | |
| SCHEMBL2599159 | 0.76 | SLC6A2 (0.61) | SLC6A2SLC6A3CHRNA1CHRNGCHRNB1 | |
| SCHEMBL2070613 | 0.76 | SLC6A2 (0.61) | SLC6A2SLC6A3CHRNA1CHRNGCHRNB1 | |
| SCHEMBL10305470 | 0.76 | SLC6A2 (0.61) | SLC6A2SLC6A3CHRNA1CHRNGCHRNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240024309-A1 | COMPOUNDS AND COMBINATIONS THEREOF FOR TREATING NEUROLOGICAL AND PSYCHIATRIC CONDITIONS | ANTECIP BIOVENTURES II LLC | 2024-01-25 | — | — | US | disclosed |
| US-11779579-B2 | Bupropion as a modulator of drug activity | ANTECIP BIOVENTURES II LLC (US) | 2023-10-10 | — | — | US | disclosed |
| US-20230277479-A1 | COMBINATION OF DEXTROMETHORPHAN AND BUPROPION FOR TREATING DEPRESSION | ANTECIP BIOVENTURES II LLC | 2023-09-07 | — | — | US | disclosed |
| US-20230277480-A1 | COMBINATION OF DEXTROMETHORPHAN AND BUPROPION FOR TREATING DEPRESSION | ANTECIP BIOVENTURES II LLC | 2023-09-07 | — | — | US | disclosed |
| US-20230263750-A1 | COMBINATION OF DEXTROMETHORPHAN AND BUPROPION FOR TREATING DEPRESSION | ANTECIP BIOVENTURES II LLC | 2023-08-24 | — | — | US | disclosed |
| US-20230255905-A1 | COMBINATION OF DEXTROMETHORPHAN AND BUPROPION FOR TREATING DEPRESSION | ANTECIP BIOVENTURES II LLC | 2023-08-17 | — | — | US | disclosed |
| US-20230241010-A1 | COMBINATION OF DEXTROMETHORPHAN AND BUPROPION FOR TREATING DEPRESSION | ANTECIP BIOVENTURES II LLC | 2023-08-03 | — | — | US | disclosed |
| US-20230225995-A1 | COMBINATION OF DEXTROMETHORPHAN AND BUPROPION FOR TREATING DEPRESSION | ANTECIP BIOVENTURES II LLC | 2023-07-20 | — | — | US | disclosed |
| US-20230218550-A1 | BUPROPION AS A MODULATOR OF DRUG ACTIVITY | ANTECIP BIOVENTURES II LLC | 2023-07-13 | — | — | US | disclosed |
| US-11690845-B2 | Methods of administering elagolix | ABBVIE INC. (US) | 2023-07-04 | — | — | US | disclosed |
| US-8440678-B2 | Pharmaceutical composition | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2013-05-14 | — | — | US | disclosed |
| US-8440678-B2 | Pharmaceutical composition | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2013-05-14 | — | — | US | disclosed |
| US-20130079404-A1 | TOPICAL FORMULATION | NUVO RESEARCH INC. (CA) | 2013-03-28 | — | — | US | disclosed |
| US-8343962-B2 | Topical formulation | NUVO RESEARCH INC. (CA) | 2013-01-01 | — | — | US | disclosed |
| US-20120010225-A1 | PHARMACEUTICAL COMPOSITION | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2012-01-12 | — | — | US | disclosed |
| US-20120010225-A1 | PHARMACEUTICAL COMPOSITION | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2012-01-12 | — | — | US | disclosed |
| US-8034820-B2 | Pharmaceutical composition | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2011-10-11 | — | — | US | disclosed |
| US-8034820-B2 | Pharmaceutical composition | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2011-10-11 | — | — | US | disclosed |
| US-20110130463-A1 | DEUTERIUM-ENRICHED BUPROPION | PROTIA, LLC (US) | 2011-06-02 | — | — | US | disclosed |
| US-20110028460-A1 | TOPICAL FORMULATION | FQUBED, INC. | 2011-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230277480-A1 | COMBINATION OF DEXTROMETHORPHAN AND BUPROPION FOR TREATING DEPRESSION | GAP43, CYP2D6, TPH1 | SLC6A2 78/4885SLC6A3 36/4885CHRNA1 136/4885 |
| US-20230255905-A1 | COMBINATION OF DEXTROMETHORPHAN AND BUPROPION FOR TREATING DEPRESSION | GAP43, CYP2D6, TPH1 | SLC6A2 77/4885SLC6A3 30/4885CHRNA1 139/4885 |
| US-20230225995-A1 | COMBINATION OF DEXTROMETHORPHAN AND BUPROPION FOR TREATING DEPRESSION | GAP43, CYP2D6, TPH1 | SLC6A2 77/4885SLC6A3 30/4885CHRNA1 139/4885 |
| US-20230241010-A1 | COMBINATION OF DEXTROMETHORPHAN AND BUPROPION FOR TREATING DEPRESSION | GAP43, CYP2D6, TPH1 | SLC6A2 77/4885SLC6A3 30/4885CHRNA1 139/4885 |
| US-20110130463-A1 | DEUTERIUM-ENRICHED BUPROPION | DBH, SLC6A3, SLC6A2 | SLC6A2 3/4885SLC6A3 2/4885CHRNA1 440/4885 |
| US-20240024309-A1 | COMPOUNDS AND COMBINATIONS THEREOF FOR TREATING NEUROLOGICAL AND PSYCHIATRIC CONDITIONS | CYP2D6, TARDBP, COMT | SLC6A2 7/4885SLC6A3 6/4885CHRNA1 346/4885 |
| US-20230277479-A1 | COMBINATION OF DEXTROMETHORPHAN AND BUPROPION FOR TREATING DEPRESSION | GAP43, CYP2D6, TPH1 | SLC6A2 78/4885SLC6A3 36/4885CHRNA1 136/4885 |
| US-20230218550-A1 | BUPROPION AS A MODULATOR OF DRUG ACTIVITY | CYP2D6, OPRM1, DBH | SLC6A2 17/4885SLC6A3 13/4885CHRNA1 183/4885 |
| US-11690845-B2 | Methods of administering elagolix | CYP2D6, CYP2B6, CYP19A1 | SLC6A2 984/4885SLC6A3 945/4885CHRNA1 1610/4885 |
| US-20230263750-A1 | COMBINATION OF DEXTROMETHORPHAN AND BUPROPION FOR TREATING DEPRESSION | GAP43, CYP2D6, TPH1 | SLC6A2 78/4885SLC6A3 36/4885CHRNA1 136/4885 |
| US-20110028460-A1 | TOPICAL FORMULATION | SPTLC1, SPTSSB, SPTLC3 | SLC6A2 480/4885SLC6A3 1164/4885CHRNA1 3454/4885 |
| US-20120010225-A1 | PHARMACEUTICAL COMPOSITION | ADORA2A, HTR2C, HTR5A | SLC6A2 12/4885SLC6A3 43/4885CHRNA1 47/4885 |
| US-11779579-B2 | Bupropion as a modulator of drug activity | CYP2D6, OPRM1, DBH | SLC6A2 17/4885SLC6A3 13/4885CHRNA1 183/4885 |
| US-20130079404-A1 | TOPICAL FORMULATION | SPTLC1, SPTLC3, SARAF | SLC6A2 317/4885SLC6A3 1251/4885CHRNA1 2194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.